CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 327-331

  Presl, Jiri ^a   Novotny, Zdenek ^a   Topolcan, Ondrej ^b   Vlasak, Pavel ^a   Kucera, Radek ^b   Fuchsova, Radka ^b   Vrzalova, Jindra ^b   Betincova, Lucie ^a   Svobodova, Sarka ^b,c  

^a Faculty Hospital in Pilsen   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CA125; Endometrial cancer; HE4; Tumor markers

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CZECH (CITIZEN); DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; PILOT STUDY; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CA125; CASE CONTROL STUDY; COMPARATIVE STUDY; ENDOMETRIUM TUMOR; FOLLOW UP; HE4; MALE; METABOLISM; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; TUMOR INVASION; TUMOR MARKERS; VERY ELDERLY;

CA125; ENDOMETRIAL CANCER; HE4; TUMOR MARKERS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PILOT PROJECTS; PREOPERATIVE CARE; PROGNOSIS; PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897023452     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, and Mangioni C: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. Journal of the National Cancer Institute 100: 1707-1716, 2008.
2. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, and Ravaggi A: Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. British J Cancer 104: 1418-1425, 2011.
3. Cibula D and Petruzelka L: Oncogynaecology. Prague: Grada Publishing, a.s., 2009.
4. DeSouza LV, Grigull J, Ghanny S, Dube V, Romaschin AD, Colgan TJ and Siu KW: Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Molecular & cellular proteomics: MCP 6: 1170-1182, 2007.
5. Duk JM, Aalders JG, Fleuren GJ and de Bruijn HW: CA125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol 155: 1097-1102, 1986.
6. Galgano MT, Hampton GM and Frierson HF Jr.: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 19: 847-853, 2006.
7. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M and Avinoach I: Tissue and serum CA125 expression in endometrial cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 12: 372-375, 2002.
8. Hawkins RE, Roberts K, Wiltshaw E, Mundy J and McCready VR: The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. British J Cancer 60: 634-637, 1989.
9. Hsieh C-H, ChangChien C-C, Lin H, Huang E-Y, Huang C-C, Lan K-C and Chang S-Y: Can a Preoperative CA 125 Level Be a Criterion for Full Pelvic Lymphadenectomy in Surgical Staging of Endometrial Cancer?. Gynecol Oncol 86: 28-33, 2002.
10. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, Jiang SW, Podratz K, Urban N and Dowdy SC: Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 124: 270-275, 2012.
11. Li H, DeSouza LV, Ghanny S, Li W, Romaschin AD, Colgan TJ and Siu KW: Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry. Journal of proteome research 6: 2615-2622, 2007.
12. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr. and Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110: 196-201, 2008.
13. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M and Lambert-Messerlian G: Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 21: 1185-1190, 2011.
14. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr., Knapp RC and Bast RC Jr.: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148: 1057-1058, 1984.
15. Novotny Z, Presl J, Kucera R, Topolcan O, Vrzalova J, Fuchsova R, Betincova L and Rokyta Z: HE4 and ROMA index in Czech postmenopausal women. Anticancer research 32: 4137-4140, 2012.
16. Powell MA: Lymph node dissection in endometrial cancer treatment - to do or not to do, that remains the question. Gynecol Oncol 127: 1-2, 2012.
17. National Cancer Registry: Cancer Incidence 2010. In: Health Statistics. Czech republic, Prague, 2013.
18. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, and Meyer T: Use of CA125 to define progression of ovarian cancer in patients with persistently elevated levels. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 19: 4054-4057, 2001.
19. Rustin GJ, Nelstrop AE, Tuxen MK and Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA125: A North Thames Ovary Group Study. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 7: 361-364, 1996.
20. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI and Berman M: Value of Preoperative CA125 Level in the Management of Uterine Cancer and Prediction of Clinical Outcome. Obstet Gynecol 90: 441-447, 1997.
21. Vuento MH, Stenman U-H, Pirhonen JP, Mäkinen JI, Laippala PJ and Salmi TA: Significance of a Single CA125 Assay Combined with Ultrasound in the Early Detection of Ovarian and Endometrial Cancer. Gynecol Oncol 64: 141-146, 1997.